Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
Eligible patients will be prescribed Desloratadine 1 tablet of 5 mg once daily. Patients will
be asked to follow-up for a final visit after 14 days (Day 15) where the safety, tolerability
and clinical efficacy will be measured.